SPYRE THERAPEUTICS, INC. Stock-Based Compensation
SPYRE THERAPEUTICS, INC. (SYRE) reported Stock-Based Compensation of $26.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $13.51M, a 44.08% increase year-over-year.
- SPYRE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $12.81M, a 44.55% increase year-over-year.
- SPYRE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $9.81M, a 6.46% increase year-over-year.
- SPYRE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $9.57M, a 26.98% decline year-over-year.
- SPYRE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $37.61M, a 16.10% decline from fiscal 2024.
- SPYRE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $44.83M, a 74.62% increase from fiscal 2023.
- SPYRE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $25.68M, a 261.06% increase from fiscal 2022.
- SPYRE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $7.11M, a 11.53% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $26.32M 10-Q · filed 2026-08-04 | $36.13M derived: sum of 3 quarters · filed 2026-08-04 | $45.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $12.81M 10-Q · filed 2026-05-05 | $22.62M derived: sum of 2 quarters · filed 2026-05-05 | $32.18M derived: sum of 3 quarters · filed 2026-05-05 | $41.56M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $9.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $19.38M derived: sum of 2 quarters · filed 2026-02-19 | $28.75M derived: sum of 3 quarters · filed 2026-08-04 | $37.61M 10-K · filed 2026-02-19 |
| 2025-09-30 | $9.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $18.94M derived: sum of 2 quarters · filed 2026-08-04 | $27.80M 10-Q · filed 2025-11-04 | $37.02M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $9.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $18.24M 10-Q · filed 2026-08-04 | $27.45M derived: sum of 3 quarters · filed 2026-08-04 | $40.55M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $8.86M 10-Q · filed 2026-05-05 | $18.07M derived: sum of 2 quarters · filed 2026-05-05 | $31.18M derived: sum of 3 quarters · filed 2026-05-05 | $39.88M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $9.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $22.32M derived: sum of 2 quarters · filed 2026-02-19 | $31.02M derived: sum of 3 quarters · filed 2026-02-19 | $44.83M 10-K · filed 2026-02-19 |
| 2024-09-30 | $13.10M 10-Q · filed 2025-11-04 | $21.80M derived: sum of 2 quarters · filed 2025-11-04 | $35.62M 10-Q · filed 2025-11-04 | $52.91M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $8.70M 10-Q · filed 2025-08-05 | $22.52M 10-Q · filed 2025-08-05 | $39.80M derived: sum of 3 quarters · filed 2026-02-19 | $44.60M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $13.84M 10-Q · filed 2025-05-08 | $31.11M derived: sum of 2 quarters · filed 2026-02-19 | $35.91M derived: sum of 3 quarters · filed 2026-02-19 | $37.80M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $17.27M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | $22.07M derived: sum of 2 quarters · filed 2026-02-19 | $23.97M derived: sum of 3 quarters · filed 2026-02-19 | $25.68M 10-K · filed 2026-02-19 |
| 2023-09-30 | $4.80M 10-Q/A · filed 2024-11-18 | $6.70M derived: sum of 2 quarters · filed 2024-11-18 | $8.40M 10-Q/A · filed 2024-11-18 | $9.84M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.90M 10-Q/A · filed 2024-11-18 | $3.62M 10-Q/A · filed 2024-11-18 | $5.04M derived: sum of 3 quarters · filed 2025-02-27 | $6.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.71M 10-Q/A · filed 2024-11-18 | $3.14M derived: sum of 2 quarters · filed 2025-02-27 | $4.70M derived: sum of 3 quarters · filed 2025-02-27 | $6.72M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.99M derived: sum of 2 quarters · filed 2025-02-27 | $5.01M derived: sum of 3 quarters · filed 2025-02-27 | $7.11M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.58M derived: sum of 2 quarters · filed 2023-11-09 | $5.68M 10-Q · filed 2023-11-09 | $7.78M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-06-30 | $2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $4.12M 10-Q · filed 2023-08-11 | $6.21M derived: sum of 3 quarters · filed 2024-11-18 | $8.32M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-03-31 | $2.10M 10-Q · filed 2023-05-11 | $4.20M derived: sum of 2 quarters · filed 2024-11-18 | $6.30M derived: sum of 3 quarters · filed 2024-11-18 | $8.38M derived: sum of 4 quarters · filed 2024-11-18 |
| 2021-12-31 | $2.09M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $4.20M derived: sum of 2 quarters · filed 2024-11-18 | $6.28M derived: sum of 3 quarters · filed 2024-11-18 | $8.04M 10-K/A · filed 2024-11-18 |
| 2021-09-30 | $2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $4.19M derived: sum of 2 quarters · filed 2022-11-03 | $5.94M 10-Q · filed 2022-11-03 | $7.56M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $3.84M 10-Q · filed 2022-08-04 | $5.45M derived: sum of 3 quarters · filed 2023-03-02 | $7.14M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $1.76M 10-Q · filed 2022-05-05 | $3.37M derived: sum of 2 quarters · filed 2023-03-02 | $5.07M derived: sum of 3 quarters · filed 2023-03-02 | $6.67M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $3.31M derived: sum of 2 quarters · filed 2023-03-02 | $4.91M derived: sum of 3 quarters · filed 2023-03-02 | $6.26M 10-K · filed 2023-03-02 |
| 2020-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.30M derived: sum of 2 quarters · filed 2021-11-04 | $4.64M 10-Q · filed 2021-11-04 | $5.83M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.95M 10-Q · filed 2021-08-05 | $4.13M derived: sum of 3 quarters · filed 2022-03-08 | $5.50M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | $1.35M 10-Q · filed 2021-05-10 | $2.53M derived: sum of 2 quarters · filed 2022-03-08 | $3.90M derived: sum of 3 quarters · filed 2022-03-08 | $5.14M derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $2.55M derived: sum of 2 quarters · filed 2022-03-08 | $3.79M derived: sum of 3 quarters · filed 2022-03-08 | $4.88M 10-K · filed 2022-03-08 |
| 2019-09-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.61M derived: sum of 2 quarters · filed 2020-11-05 | $3.69M 10-Q · filed 2020-11-05 | $5.07M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $2.33M 10-Q · filed 2020-08-10 | $3.70M derived: sum of 3 quarters · filed 2021-03-18 | $4.78M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $1.08M 10-Q · filed 2020-05-07 | $2.46M derived: sum of 2 quarters · filed 2021-03-18 | $3.53M derived: sum of 3 quarters · filed 2021-03-18 | $4.53M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $2.45M derived: sum of 2 quarters · filed 2021-03-18 | $3.44M derived: sum of 3 quarters · filed 2021-03-18 | $4.28M 10-K · filed 2021-03-18 |
| 2018-09-30 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $2.07M derived: sum of 2 quarters · filed 2019-11-06 | $2.90M 10-Q · filed 2019-11-06 | $3.60M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $996.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.83M 10-Q · filed 2019-08-06 | $2.53M derived: sum of 3 quarters · filed 2020-02-24 | $3.26M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $835.00K 10-Q · filed 2019-05-07 | $1.53M derived: sum of 2 quarters · filed 2020-02-24 | $2.26M derived: sum of 3 quarters · filed 2020-02-24 | $2.93M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $698.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $1.43M derived: sum of 2 quarters · filed 2020-02-24 | $2.09M derived: sum of 3 quarters · filed 2020-02-24 | $2.49M 10-K · filed 2020-02-24 |
| 2017-09-30 | $728.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.39M derived: sum of 2 quarters · filed 2018-11-08 | $1.79M 10-Q · filed 2018-11-08 | $2.05M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $665.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $1.07M 10-Q · filed 2018-08-09 | $1.32M derived: sum of 3 quarters · filed 2019-03-07 | $1.76M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $401.00K 10-Q · filed 2018-05-08 | $659.00K derived: sum of 2 quarters · filed 2019-03-07 | $1.09M derived: sum of 3 quarters · filed 2019-03-07 | $1.48M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $258.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $692.00K derived: sum of 2 quarters · filed 2019-03-07 | $1.08M derived: sum of 3 quarters · filed 2019-03-07 | $1.22M 10-K · filed 2019-03-07 |
| 2016-09-30 | $434.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $823.00K derived: sum of 2 quarters · filed 2017-11-07 | $963.00K 10-Q · filed 2017-11-07 | $1.38M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-06-30 | $389.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $529.00K 10-Q · filed 2017-08-09 | $948.00K derived: sum of 3 quarters · filed 2018-03-13 | $1.11M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-03-31 | $140.00K 10-Q · filed 2017-05-09 | $559.00K derived: sum of 2 quarters · filed 2018-03-13 | $723.00K derived: sum of 3 quarters · filed 2018-03-13 | $869.00K derived: sum of 4 quarters · filed 2018-03-13 |
| 2015-12-31 | $419.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $583.00K derived: sum of 2 quarters · filed 2018-03-13 | $729.00K derived: sum of 3 quarters · filed 2018-03-13 | $767.00K 10-K · filed 2018-03-13 |
| 2015-09-30 | $164.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $310.00K derived: sum of 2 quarters · filed 2016-11-09 | $348.00K 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $184.00K 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $38.00K 10-Q · filed 2016-05-19 | |||
| 2014-12-31 | $147.00K 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |